3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2$l^{6},1,3-benzothiadiazine-2,2-dione
![]() |
- $643 - $918
- Product name: 3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2$l^{6},1,3-benzothiadiazine-2,2-dione
- CAS: 79099-04-0
- MF: C19H23N3O2S
- MW: 357.47
- EINECS:
- MDL Number:MFCD25948726
- Synonyms:3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2$l^{6},1,3-benzothiadiazine-2,2-dione;3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2,1,3-benzothiadiazine 2,2-dioxide;3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2LAMBDA(6),1,3-benzothiadiazine-2,2-dione;1H-2,1,3-Benzothiadiazine, 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-, 2,2-dioxide
2 prices
Selected condition:
Brand
- AK Scientific
- Matrix Scientific
Package
- 500mg
- ManufacturerAK Scientific
- Product number9805AE
- Product description3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2lambda(6),1,3-benzothiadiazine-2,2-dione
- Packaging500mg
- Price$918
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number101517
- Product description3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2LAMBDA(6),1,3-benzothiadiazine-2,2-dione >97%
- Packaging500mg
- Price$643
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 9805AE | 3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2lambda(6),1,3-benzothiadiazine-2,2-dione | 500mg | $918 | 2021-12-16 | Buy |
Matrix Scientific | 101517 | 3-(1-Benzylpiperidin-4-yl)-3,4-dihydro-1H-2LAMBDA(6),1,3-benzothiadiazine-2,2-dione >97% | 500mg | $643 | 2021-12-16 | Buy |
Properties
Boiling point :504.1±60.0 °C(Predicted)
Density :1.279±0.06 g/cm3(Predicted)
pka :7.43±0.20(Predicted)
Density :1.279±0.06 g/cm3(Predicted)
pka :7.43±0.20(Predicted)
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|